Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Trends and outcomes in ALS patients with PEG tubes
Neuromuscular and Clinical Neurophysiology (EMG)
Neuromuscular and Clinical Neurophysiology (EMG) Posters (7:00 AM-5:00 PM)
042

To analyze the trends and outcomes of PEG tube placement in patients with ALS.
Dysphagia is one of the most severe complications associated with amyotrophic lateral sclerosis (ALS) that leads to increased incidence of aspiration pneumonia, weight loss, failure to thrive and eventually low nutritional status. It has thus been recognized as a negative prognostic factor. Percutaneous endoscopic gastrotomy (PEG) tube placement has shown to avoid these complications and improve overall nutritional status in patients with ALS

After obtaining IRB waiver, data was collected from Cerner Health Facts ® and patients admitted to hospitals with a primary diagnosis of ALS using ICD9 and ICD10 codes were included in our study. Comparison of variables including demographics, length of stay and outcomes was done using χ2 test for categorical data and t-test for continuous variables. Multivariate logistic regression was done to identify the association between each group and their variables.

A total of 4689 ALS patients from 2010-2018 (337 with PEG tube and 4352 without PEG tube) were included in the study. The mean age of ALS patients with PEG tube was 63.5 as compared to 62.03 in patients without PEG tube (p<0.05) and 49.6% of patients with PEG tube were male as compared to 55.4% in the other group (p<0.05). 19.9% of patients with PEG tube were discharged to a facility as compared to 4.4% without the PEG tube (p<0.01). Hypertension was the most common comorbidity in both patient groups (40.1% in patients with PEG tube and 11.5% in patients without PEG tube, p <0.0001). Multivariate analysis showed that the odds ratio of patient with PEG tube being discharged to a facility was 1.823 [95% CI, 1.248-2.664, p<0.005].

PEG tube placement was associated with discharge to facility as compared to a patient without PEG tube.  
Authors/Disclosures
Tejas R. Mehta, MD
PRESENTER 		Dr. Mehta has nothing to disclose.
Swathi Beladakere Ramaswamy, MD Dr. Beladakere Ramaswamy has nothing to disclose.
Sachin M. Bhagavan, MD Dr. Bhagavan has nothing to disclose.
No disclosure on file
Raghav Govindarajan, MD, FÂ鶹´«Ã½Ó³»­ (HSHS St. Elizabeth Medical Group) Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for MT pharma. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Catalyst. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche . Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amicus. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Govindarajan has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for MT pharma . Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Catalyst. Dr. Govindarajan has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Argenx. Dr. Govindarajan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biohaven. Dr. Govindarajan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for UCB. Dr. Govindarajan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Takeda. Dr. Govindarajan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Abbvie. The institution of Dr. Govindarajan has received research support from Band of Hope . The institution of Dr. Govindarajan has received research support from Alexion. Dr. Govindarajan has received publishing royalties from a publication relating to health care.